Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07214922) titled 'Relative Bioavailability of Evobrutinib Tablet Batches' on Oct. 8.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Other. Masking: None (Open Label).
Primary Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Condition:
Healthy
Intervention:
Drug: Treatment A
Drug: Treatment B
Drug: Treatment C
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: January 18, 2023
Target Sample Size: 28
Countries of Recruitment:
Germany
To know more, visit https://clinicaltr...